Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery

Bioconjugate Chemistry

Volumn 23, Issue 8, 2012, Pages 1610-1622

  Pilkington Miksa, Michael ^a   Arosio, Daniela ^b   Battistini, Lucia ^c   Belvisi, Laura ^a   De Matteo, Marilenia ^a   Vasile, Francesca ^a   Burreddu, Paola ^d   Carta, Paola ^e   Rassu, Gloria ^d   Perego, Paola ^f   Carenini, Nives ^f   Zunino, Franco ^f   De Cesare, Michelandrea ^f   Castiglioni, Vittoria ^a,g   Scanziani, Eugenio ^a,g   Scolastico, Carlo ^a   Casiraghi, Giovanni ^c   Zanardi, Franca ^c   Manzoni, Leonardo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d CNR   (Italy)

^e Porto Conte Ricerche Srl   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Mouse and Animal Pathology Laboratory   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; ETHYLENE GLYCOL; TARGETED DRUG DELIVERY; TUMORS;

ANTI-TUMORS; BIOLOGICAL EVALUATION; CELL SENSITIVITY; DESIGN EVALUATION; DESIGN SYNTHESIS; INTEGRINS; PACLITAXEL; SYNTHESIS EVALUATION; TAXANES; THERAPEUTIC INDEX;

ETHYLENE;

ALPHAVBETA5 INTEGRIN; ETHYLENE GLYCOL; PACLITAXEL; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL SURVIVAL; CONTROLLED STUDY; COVALENT BOND; DRUG DESIGN; DRUG SOLUBILITY; DRUG SYNTHESIS; ENDOCYTOSIS; FEASIBILITY STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO CULTURE; MITOSIS; MOUSE; NONHUMAN; OVARY CARCINOMA; RECEPTOR BINDING; TARGETED GENE REPAIR; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84865138567     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300164t     Document Type: Article

References (49)

1. Cossa, G., Gatti, L., Zunino, F., and Perego, P. (2009) Strategies to improve the efficacy of platinum compounds Curr. Med. Chem. 16, 2355-2365
2. Desgrosellier, J. S. and Cheresh, D. A. (2010) Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10, 9-22
3. Harms, J. F., Welch, D. R., Samant, R. S., Shevde, L. A., Miele, M. E., Babu, G. R., Goldberg, S. F., Gilman, V. R., Sosnowski, D. M., Campo, D. A., Gay, C. V., Budgeon, L. R., Mercer, R., Jewell, J., Mastro, A. M., Donahue, H. J., Erin, N., Debies, M. T., Meehan, W. J., Jones, A. L., Mbalaviele, G., Nickols, A., Christensen, N. D., Melly, R., Beck, L. N., Kent, J., Rader, R. K., Kotyk, J. J., Pagel, M. D., Westlin, W. F., and Griggs, D. W. (2004) A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis Clin. Exp. Metastasis 21, 119-128 (Pubitemid 38988085)
4. Vellon, L., Menendez, J. A., and Lupu, R. (2006) A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2MAPK" connection regulates the proliferation of breast cancer cells Mol. Carcinog. 45, 795-804 (Pubitemid 44484990)
5. Gingras, M. C., Roussel, E., Bruner, J. M., Branch, C. D., and Moser, R. P. (1995) Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue J. Neuroimmunol. 57, 143-153
6. Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., and Buck, C. A. (1990) Integrin distribution in malignant melanoma: association of the beta3 subunit with tumor progression Cancer Res. 50, 6757-6764 (Pubitemid 20348810)
7. Dang, D., Bamburg, J. R., and Ramos, D. M. (2006) Alphavbeta3 integrin and cofilin modulate K1735 melanoma cell invasion Exp. Cell Res. 312, 468-477 (Pubitemid 41804111)
8. Cooper, C. R., Chay, C. H., and Pienta, K. J. (2002) The role of alpha(v)beta(3) in prostate cancer progression Neoplasia 4, 191-194 (Pubitemid 34525250)
9. Hapke, S., Kessler, H., Luber, B., Benge, A., Hutzler, P., Hofler, H., Schmitt, M., and Reuning, U. (2003) Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/vitronectin interaction Biol. Chem. 384, 1073-1083 (Pubitemid 37062968)
10. 3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides Curr. Med. Chem. 17, 1255-1299
11. Paolillo, M., Russo, M. A., Serra, M., Colombo, L., and Schinelli, S. (2009) Small molecule integrin antagonists in cancer therapy Mini-Rev. Med. Chem. 9, 1439-1446
12. 3 integrin antagonist J. Med. Chem. 42, 3033-3040 (Pubitemid 29384038)
13. Manzoni, L., Belvisi, L., Arosio, D., Civera, M., Pilkington-Miksa, M., Potenza, D., Caprini, A., Araldi, E. M. V., Monferini, E., Mancino, M., Podestà, F., and Scolastico, C. (2009) Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting ChemMedChem 4, 615-632
14. Battistini, L., Burreddu, P., Carta, P., Rassu, G., Auzzas, L., Curti, C., Zanardi, F., Manzoni, L., Araldi, E. M. V., Scolastico, C., and Casiraghi, G. (2009) 4-Aminoproline-based arginine-glycine-aspartate integrin binders with exposed ligation points: practical in-solution synthesis, conjugation and binding affinity evaluation Org. Biomol. Chem. 7, 4924-4935
15. 3-targeted cancer therapy Drug Dev. Res. 69, 329-339
16. Stupp, R. and Ruegg, C. (2007) Integrin inhibitors reaching the clinic J. Clin. Oncol. 25, 1637-1638 (Pubitemid 46797938)
17. Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., ONeill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., Schiff, D., Shapiro, W. R., Burdette-Radoux, S., Dropcho, E. J., Wittemer, S. M., Nippgen, J., Picard, M., and Nabors, B. L. (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J. Clin. Oncol. 26, 5610-5617
18. MacDonald, T. J., Stewart, C. F., Kocak, M., Goldman, S., Ellenbogen, R. G., Phillips, P., Lafond, D., Young Poussaint, T., Kieran, M. W., Boyett, J. M., and Kun, L. E. (2008) Phase I clinical trial of Cilengitide in children with refractory brain tumors: pedriatric brain tumor consortium study PBTC-012 J. Clin. Oncol. 26, 919-924 (Pubitemid 351398085)
19. 3-integrin expression in vivo Acc. Chem. Res. 42, 969-980
20. Garanger, E., Boturyn, D., and Dumy, P. (2007) Tumor targeting with RGD peptide ligands - Design of new molecular conjugates for imaging and therapy of cancers Anti Cancer Agents Med. Chem. 7, 552-558 (Pubitemid 351836126)
21. Temming, K., Schiffelers, R. M., Molema, G., and Kok, R. J. (2005) RGD-Based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature Drug Resistance Updates 8, 381-402 (Pubitemid 43358061)
22. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279, 377-380 (Pubitemid 28063372)
23. Liu, Y., Bajjuri, K. M., Liu, C., and Sinha, S. C. (2012) Targeting cell surface alpha(v)beta(3,5) integrins increases therapeutic efficacies of a legumain protease-activated auristatin prodrug Mol. Pharm. 9, 168-175
24. Dufort, S., Sancey, L., Hurbin, A., Foillard, S., Boturyn, D., Dumy, P., and Coll, J.-L. (2011) Targeted delivery of a proapoptotic peptide to tumors in vivo J. Drug Targeting 19, 582-588
25. 3 integrin ligands: an approach to tumor-targeted therapy Bioconjugate Chem. 21, 1956-1967
26. 3 integrin for therapy Int. J. Med. Sci. 7, 326-339
27. 3 Int. J. Pharm. 368, 89-97
28. Chen, X., Plasencia, C., Hou, Y., and Neamati, N. (2005) Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 48, 1098-1106 (Pubitemid 40270453)
29. (corrigendum (2005) J. Med. Chem. 48, 5874).
30. Cao, Q., Li, Z.-B., Chen, K., Wu, Z., He, L., Neamati, N., and Chen, X. (2008) Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer Eur. J. Nucl. Med. Mol. Imaging 35, 1489-1498
31. Arosio, D., Casagrande, C., and Manzoni, L. (2012) Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles Curr. Med. Chem. 19, 3128-3151
32. Zhan, C., Meng, Q., Li, Q., Feng, L., Zhu, J., and Lu, W. (2012) Cyclic RGD-Polyethylene Glycol-Polyethylenimine for Intracranial Glioblastoma-Targeted Gene Delivery Chem. Asian J. 7, 91-96
33. Yao, H.-J., Ju, R.-J., Wang, X.-X., Zhang, Y., Li, R.-J., Yu, Y., Zhang, L., and Lu, W.-L. (2011) The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery Biomaterials 32, 3285-3302
34. Eldar-Boock, A., Miller, K., Sanchis, J., Lupu, R., Vicent, M. J., and Satchi-Fainaro, R. (2011) Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel Biomaterials 32, 3862-3874
35. Austin, L. A., Kang, B., Yen, C.-W., and El-Sayed, M. A. (2011) Nuclear targeted silver nanospheres perturb the cancer cell cycle differently than those of nanogold Bioconjugate Chem. 22, 2324-2331
36. Ubezio, P., Garofalo, A., Borsotti, P., Cassis, L., Riccardi, E., Scanziani, E., Eccles, S. A., Bani, M. R., and Giavazzi, R. (2006) The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis Clin. Cancer Res. 12, 1839-1849
37. Dijkgraaf, I., Rijnders, A. Y., Soede, A., Dechesne, A. C., van Esse, G. W., Brouwer, A. J., Corstens, F. H. M., Boerman, O. C., Rijkers, D. T. S., and Liskamp, R. M. (2007) Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes Org. Biomol. Chem. 5, 935-944 (Pubitemid 46375649)
38. Benard, J., Da Silva, J., De Blois, M. C., Boyer, P., Duvillard, P., Chiric, E., and Riou, G. (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice Cancer Res. 45, 4970-4979 (Pubitemid 16236181)
39. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino, F. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res. 56, 556-562 (Pubitemid 26043653)
40. Kingston, D. G. (2000) Recent advances in the chemistry of taxol J. Nat. Prod. 63, 726-734 (Pubitemid 30395547)
41. Himo, F., Lovell, T., Hilgraf, R., Rostovtsev, V. V., Noodleman, L., Sharpless, K. B., and Fokin, V. V. (2005) Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates J. Am. Chem. Soc. 127, 210-216 (Pubitemid 40094384)
42. Wester, H. J. and Kessler, H. (2005) Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J. Nucl. Med. 46, 1940-1945 (Pubitemid 46657438)
43. 3 with a tetrameric RGD-synthetic peptide Mol. Ther. 17, 837-843
44. 3-positive breast cancer Bioconjugate Chem. 18, 438-446 (Pubitemid 46493515)
45. Staros, J. V. (1982) N -Hydroxysulfosuccinimide active esters: bis(N -hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers Biochemistry 21, 3950-3955
46. Anjaneyulu, P. S. R. and Staros, J. V. (1987) Reactions of N -hydroxysulfosuccinimide active esters Int. J. Pept. Protein Res. 30, 117-124
47. Matson, D. R. and Stukenberg, P. T. (2011) Spindle poisons and cell fate: a tale of two pathways Mol. Interv. 11, 141-150
48. Portugal, J., Mandilla, S., and Bataller, M. (2010) Mechanisms of drug-induced mitotic catastrophe in cancer cells Curr. Pharm. Des. 16, 69-78
49. Roninson, I. B., Broude, E. V., and Chang, B. D. (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells Drug Res. Updates 4, 303-313 (Pubitemid 34456384)